Arginine deprivation in cancer therapy

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 18, Issue 1, 2015, Pages 78-82

  Feun, Lynn G ^a   Kuo, Macus Tien ^b   Savaraj, Niramol ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Arg; Arg deiminase; Arginase; Cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINASE; ARGININE; ARGININE DEIMINASE; ARGININOSUCCINATE LYASE; ARGININOSUCCINATE SYNTHASE; ARGININOSUCCINATE SYNTHETASE 1; CHLOROQUINE; PEGARGIMINASE; PEGYLATED RECOMBINANT HUMAN ARGINASE 1; PEMETREXED; PLACEBO; RECOMBINANT ENZYME; RECOMBINANT HUMAN ARGINASE 1; UNCLASSIFIED DRUG; HYDROLASE; MACROGOL DERIVATIVE;

ABDOMINAL DISCOMFORT; BLADDER CANCER; CANCER THERAPY; CLINICAL TRIAL (TOPIC); CUTANEOUS MELANOMA; DIARRHEA; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GLIOBLASTOMA; HUMAN; LIVER CELL CARCINOMA; MELANOMA; NASOPHARYNX CARCINOMA; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; PROTEIN EXPRESSION; REVIEW; UVEA MELANOMA; METABOLISM; NEOPLASMS;

ANTINEOPLASTIC AGENTS; ARGINASE; ARGININE; ARGININOSUCCINATE SYNTHASE; HUMANS; HYDROLASES; NEOPLASMS; POLYETHYLENE GLYCOLS;

EID: 84916624777     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000122     Document Type: Review

References (22)

1. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998; 28: 97-113.
2. Feun L, You M, Wu CJ, et al. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des 2008; 14: 1049-1057.
3. Phillips MM, Sheaff MT, Szlosarek PW. Targeting arginine-dependent cancers with arginine-degrading enzymes: Opportunities and challenges. Cancer Res Treat 2013; 45: 251-262.
4. Huang HY, Wu WR, Wang YH, et al. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: Aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res 2013; 19: 2861-2872.
5. Syed N, Langer J, Janczar K, et al. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis 2013; 4: E458.
6. Lan J, Tai HC, Lee SW, et al. Deficiency in expression and epigenetic DNA Methylation of ASS1 gene in nasopharyngeal carcinoma: Negative prognostic impact and therapeutic relevance. Tumour Biol 2014; 35: 161-169.
7. Wu L, Li L, Meng S, et al. Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2013; 28: 365-368.
8. Allen MD, Luong P, Hudson C, et al. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res 2014; 74: 896-907.
9. You M, Savaraj N, Kuo MT, et al. TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. Mol Cell Biochem 2013; 374: 181-190.
10. Long Y, Tsai WB, Wangpaichitr M, et al. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol Cancer Ther 2013; 12: 2581-2590.
11. Wang Z, Shi X, Li Y, et al. Involvement of autophagy in recombinant human arginase-induced cell apoptosis and growth inhibition of malignant melanoma cells. Appl Microbiol Biotechnol 2014; 98: 2485-2494.
12. Tanios R, Bekdash A, Kassab E, et al. Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells. Leuk Res 2013; 37: 1565-1571.
13. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005; 294: 81-90.
14. Kwong-Lam F, Chi-Fung CG. Vincristine could partly suppress stromal support to T-ALL blasts during pegylated arginase I treatment. Exp Hematol Oncol 2013; 2: 11.
15. Wells JW, Evans CH, Scott MC, et al. Arginase treatment prevents the recovery of canine lymphoma and osteosarcoma cells resistant to the toxic effects of prolonged arginine deprivation. PLoS One 2013; 8: E54464.
16. Huang HL, Hsu HP, Shieh SC, et al. Attenuation of argininosuccinate lyase inhibits cancer growth via cyclin A2 and nitric oxide. Mol Cancer Ther 2013; 12: 2505-2516.
17. Vynnytska-Myronovska B, Kurlishchuk Y, Bobak Y, et al. Three-dimensional environment renders cancer cells profoundly less susceptible to a single amino acid starvation. Amino Acids 2013; 45: 1221-1230.
18. Yau T, Cheng PN, Chan P, et al. A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest New Drugs 2013; 31: 99-107.
19. Szlosarek PW, Luong P, Phillips MM, et al. Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J Clin Oncol 2013; 31: E111-e113.
20. Ott PA, Carvajal RD, Pandit-Taskar N, et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs 2013; 31: 425-434.
21. Feun LG, Marini A, Walker G, et al. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from argininedepleting therapy with pegylated arginine deiminase. Br J Cancer 2012; 106: 1481-1485.
22. Yoon JK, Frankel AE, Feun LG, et al. Arginine deprivation therapy for malignant melanoma. Clin Pharmacol 2013; 5: 11-19.